The complete guide to Saxenda (liraglutide) — the original weight-loss GLP-1

Saxenda (liraglutide 3.0mg) was the first GLP-1 receptor agonist approved specifically for chronic weight management, receiving FDA approval in 2014. While newer medications have since surpassed it in efficacy, Saxenda remains available and is still prescribed for patients who don't tolerate or respond to semaglutide or tirzepatide.

How Saxenda works

Like other GLP-1 medications, Saxenda activates the GLP-1 receptor to reduce appetite, slow gastric emptying, and modulate the brain's reward response to food. The key difference is that liraglutide has a shorter duration of action than semaglutide or tirzepatide, which is why it requires daily injection rather than weekly.

What the clinical trials show

• •SCALE trial: The pivotal weight loss trial showed approximately 8% body weight loss at the maximum dose of 3.0mg over 56 weeks. About one-third of participants achieved 5% or more weight loss.
• •In the real world, results tend to be more modest — approximately 5-6% body weight loss at one year.

To put this in context: tirzepatide achieves 20.9% and semaglutide achieves 14.9% in their pivotal trials. Saxenda's 8% is meaningful but substantially less.

Dosing schedule

Saxenda titrates weekly with daily injections:

• •Week 1: 0.6mg daily
• •Week 2: 1.2mg daily
• •Week 3: 1.8mg daily
• •Week 4: 2.4mg daily
• •Week 5+: 3.0mg daily (maximum)

The daily injection schedule is the biggest practical difference from newer weekly options. For some patients, the daily routine actually helps with adherence — it becomes part of the morning or evening habit.

Side effects

• •Nausea: Most common in the first 2 weeks, tends to fade more quickly than with newer GLP-1s because the doses are lower.
• •Hypoglycemia: Rare unless combined with insulin or sulfonylureas.
• •Headache: Often tied to under-eating or dehydration.

Overall, Saxenda's side effect profile is generally milder than semaglutide or tirzepatide, simply because the GLP-1 receptor activation is less potent.

When Saxenda makes sense

Saxenda is worth considering if you've tried semaglutide or tirzepatide and couldn't tolerate the side effects, if you prefer a gentler approach to GLP-1 therapy, or if insurance covers Saxenda but not newer options.

It's also sometimes used as a bridge — starting with Saxenda to gauge GLP-1 tolerance before transitioning to a more potent weekly option.

Cost and access

Saxenda's list price is approximately $1,349/month — similar to Wegovy despite lower efficacy. Novo Nordisk offers a savings program. Insurance coverage varies widely.

The bottom line

Saxenda is the founding member of the weight-loss GLP-1 family. While newer medications offer substantially better efficacy, Saxenda remains a viable option for patients who need a gentler introduction to GLP-1 therapy or who can't tolerate the more potent options. Every person's response to medication is individual — what matters is finding the option that works for you.